Dodoo Cornelius C, Wang Jie, Basit Abdul W, Stapleton Paul, Gaisford Simon
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK.
UCL School of Pharmacy, University College London, 29-39 Brunswick Square, London, WC1N 1AX, UK; Intract Pharma, 29-39 Brunswick Square, London, WC1N 1AX, UK.
Int J Pharm. 2017 Sep 15;530(1-2):224-229. doi: 10.1016/j.ijpharm.2017.07.068. Epub 2017 Jul 29.
The aim of this work was to assess the viability of some commercial probiotics after exposure to gastric acid and the possibility of modifying these formulations for delivery into the distal parts of the intestines. Gastrointestinal tolerance testing was conducted for three commercial probiotics and an in-house freeze-dried Lactobacillus acidophilus strain. The contents of the commercial products and the in-house freeze-dried strain were then loaded into capsules for site-specific delivery into the colon using the Phloral coating technology; the viability upon release was then ascertained. An assessment of the potential of these products to adhere to intestinal cells was also conducted. The results showed that all the commercial products contained the minimum number of probiotic strains as indicated on their respective packages. When gastric acid tolerance tests were performed on these products, all the commercial probiotics and the prepared freeze-dried strain demonstrated over 10 CFU reductions within 5min. When these were encapsulated for site-specific delivery into the distal parts of the gut, viabilities of approximately 90% were obtained after these capsules had been initially deposited in gastric acid for 2h. An evaluation of the ability of the probiotic formulations to adhere to intestinal cells demonstrated adhesion in the range 64-76% for the products evaluated. The need to target the delivery of probiotics into the intestines has been demonstrated here as this offers a greater potential for colonisation of the intestines once the harshness of the stomach has been overcome.
这项工作的目的是评估一些市售益生菌在暴露于胃酸后的生存能力，以及修改这些制剂以便将其递送至肠道远端的可能性。对三种市售益生菌和一种内部冻干嗜酸乳杆菌菌株进行了胃肠道耐受性测试。然后，使用间苯二酚涂层技术将市售产品和内部冻干菌株的内容物装入胶囊，以便将其定点递送至结肠；随后确定释放时的生存能力。还对这些产品黏附于肠道细胞的潜力进行了评估。结果表明，所有市售产品所含益生菌菌株数量均为各自包装上标明的最低数量。对这些产品进行胃酸耐受性测试时，所有市售益生菌和制备的冻干菌株在5分钟内的CFU减少量均超过10。当将这些产品封装以便定点递送至肠道远端时，这些胶囊最初在胃酸中放置2小时后，其生存能力约为90%。对益生菌制剂黏附于肠道细胞的能力进行的评估表明，所评估产品的黏附率在64%至76%之间。此处已证明将益生菌递送至肠道的必要性，因为一旦克服了胃部的恶劣环境，这为肠道定殖提供了更大的潜力。
